Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Kirsten van Nimwegen
ResearcherPublications, citations & collaboration network
Kirsten van Nimwegen is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 7 works, 82 citations, an h-index of 2 and an i10-index of 1.
7
Works
82
Citations
2
h-index
1
i10-index
IDs:OpenAlex
How has Kirsten van Nimwegen's publication output changed over time?
ScholarIQpublication output · 2017–2025
Output grew0% over the shown period — from 1 works in 2017 to 1 in 2025.
1
1
1
3
1
20172018201920232025
What are the most-cited papers on Kirsten van Nimwegen?
ScholarIQmost cited works
Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment
Lieneke F.M. Ariëns, Kirsten van Nimwegen, M Shams, David De Bruin, Jorien van der Schaft, Harmieke van Os‐Medendorp, Marjolein de Bruin‐Weller
Acta Dermato Venereologica. 201977 CitationsOPEN ACCESS
P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK
Ivan Špıčka, Ido Lapidot, Maximilian Merz, Jakub Radocha, Martin Štork, Tomáš Jelı́nek, Alexandra Jungová, Jiří Minařík, J. Soukup, Michel van Speybroeck, Nolen Joy Perualila, Joris Diels, João Duarte Mendes, Kirsten van Nimwegen, Kai Strobel, S Wischlen, Henrik Sliwka, Blanca Gros Otero, Roman Hájek
S4210211592. 20232 CitationsOPEN ACCESS
P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
Philippe Moreau, Niels W.C.J. van de Donk, Michel Delforge, Hermann Einsele, Valerio De Stefano, Aurore Perrot, Britta Besemer, Charlotte Pawlyn, Lionel Karlin, Salomon Manier, Xavier Leleu, Pushpike Thilakarathne, Joris Diels, Katharine S. Gries, Nichola Erler-Yates, Kirsten van Nimwegen, Raúl Balsera Moraño, Vadim Strulev, Imène Haddad, Rachel Kobos, Jennifer Smit, Alexander Mclean Marshall, Mary Slavcev, María‐Victoria Mateos, Katja Weisel
S4210211592. 20231 CitationsOPEN ACCESS
P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison
Michel Delforge, Sébastien Anguille, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Van de Broek, Joris Diels, Nichola Erler-Yates, Sébastien Van Causenbroeck, Kirsten van Nimwegen, Sophie Vandervennet, Susanne Lub, Marie-Christiane Madeleine Vekemans
S186546955. 20231 Citations
Inpatient vs outpatient treatment management with teclistamab in relapsed and refractory multiple myeloma: A cost and healthcare resource utilization analysis
Niels W.C.J. van de Donk, Ruth Wester, Inger S. Nijhof, Claire Albrecht, Raúl Balsera Moraño, Cristina Entrala, Kirsten van Nimwegen
Blood. 20251 CitationsOPEN ACCESS
Related on ScholarIQ
Becton Dickinson (Netherlands)
Institution
Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment
Paper
P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK
Paper
P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
Paper
P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison
Paper
Inpatient vs outpatient treatment management with teclistamab in relapsed and refractory multiple myeloma: A cost and healthcare resource utilization analysis
Paper